Press release says
WASHINGTON, June 30, 2021 /PRNewswire/ — LexisNexis® Legal & Professional announced today that the United States Patent and Trademark Office (USPTO) awarded LexisNexis Reed Tech a 10-year patent data and document management contract. Reed Tech has been a partner to the USPTO for over 5 decades, providing services both in the patent application and patent evaluation and assessment processes.
The partnership between LexisNexis Reed Tech and the USPTO began in 1969 to further enable the USPTO’s commitment to digital transformation. From the initial investment in the development of a computer system to streamline the patent publishing process to the digitalization of patent records over the last decade, this partnership has focused on making more information available to the public and streamlining the work of enterprises, attorneys, and entrepreneurs. Over the decades, Reed Tech processed over 7 million of the total 11 million+ patents issued by the USPTO to date (as of May 2021).
“We are pleased to be selected by the USPTO and look forward to continuing our partnership for the next 10 years,” said Andrew Matuch, President, LexisNexis Reed Tech & Intellectual Property Solutions. “The incredible work done by our patent operations team each and every day is what enables the innovation ecosystem to be more effective and efficient at bringing meaningful innovation to our world.”
Reed Tech has a team of more than 800 experts in their fields, taking on the responsibility of supporting the publication of U.S. patent grants and patent applications. These services include performing intake and quality reviews, converting image files to searchable text documents, updating content to reflect USPTO business rules, creating image and XML versions of patent applications and patent grants, and preparing content for publication at several stages in the patent examination lifecycle.
With this new 10-year contract, LexisNexis Reed Tech further cements its unique position as a partner and solution provider to a diverse mix of audiences ranging from Intellectual Property departments and Government institutions to life sciences and pharmaceutical manufacturers.
